BioSpace News Archive

-- Updated Phase 2 results for hepcidin mimetic PTG-300 in polycythemia vera accepted for oral presentation at the ASH Annual Meeting in December 2020 -- -- PTG-300 received European Medicine Agency (EMA) Orphan Drug Designation for the treatment of polycythemia vera -- -- Company is advancing additional oral IL-23 receptor antagonists into clinical development in collaboration with Janssen --

XPhyto Therapeutics Corp., a next-generation bioscience accelerator, is pleased to announce the appointment of Mr. Per S. Thoresen to the Company’s board of directors effective immediately.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has authorized the repurchase of up to $25 million of the Company’s shares of common stock. “This share repurchase program reflects our confidence in the long-term outlook for the Company, including our ability to generat

Rare Pediatric Disease Designation received from FDA for TK216 for treatment of Ewing s arcoma Interim Phase 1 data for TK216 in 15 evaluable patients with relapsed/refractory Ewing s arcoma demonstrated two complete responses , with no relapses after complete response Strengthened the balance sheet by securing $ 10.1 million in equity financing during Q3 2020

10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, November 16 at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.10xgenomics.com About 10x Genomics 10x Ge

Amnio Technology, LLC, a global leader in the development and distribution of amniotic tissue allografts, is announcing today that it has received authorization from FDA to proceed with a Phase 2 clinical trial under an Investigational New Drug (IND) application for its amniotic tissue-based product, PalinGen® Flow.

MorphoSys AG Prime Standard Segment; MDAX & TecDAX; announced that multiple abstracts regarding the company’s proprietary key asset tafasitamab have been accepted for poster presentations and online publication at the upcoming 62nd ASH Virtual Annual Meeting and Exposition from December 05-December 08, 2020.

Viemed Healthcare, Inc., a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced that it has reported its financial results for the three and nine months ended September 30, 2020.

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results for the third quarter ended September 30, 2020, and recent corporate highlights.

MorphoSys AG will publish its results for the third quarter and first 9-month of 2020 on November 11, 2020 at 10:00pm CET.